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ABSTRACT: 
Background: Tuberculosis  remains  a major public health threat.   Studies  have   shown that 
medium chain fatty acids (MCFA), such as, those found in Virgin Coconut Oil (VCO),  possess 
activity against a wide range of microorganisms including Mycobacterium  tuberculosis. The 
goal of the study was to determine the in-vitro susceptibility of M. tuberculosis (TB) isolates to 
two commercial brands of VCOs each containing different amounts of lauric acid and produced 
by two different extraction processes. Two brands of VCO were tested for their anti-TB actions 
compared  to  pure  lauric  acid  and  a  negative  control.  Two  replicate  runs  were  done.  VCO 
samples were inoculated with 0.1 mL of the H37RV strain of M. tuberculosis and incubated at 
37
0C with shaking for 5 days. After incubation, the mixtures were diluted 10-fold up to 10
-4 
concentration to obtain countable colonies using Middlebrook 7H10 agar plates and Lowenstein-
Jensen (L-J) slants. Colony growths of M. tuberculosis were examined in each dilution every 
week for three to eight weeks. 
 
Results:  Both brands of VCO at increasing dilution from 1:10 to 1:10000 lowered the colony 
counts of M. tuberculosis by 46% to 100 % on the Middlebrook 7H10 agar.  Similar results were 
noted on L-J slants with colony counts decreasing by 25% to 96%. Lauric acid solution showed 
complete inhibition of bacterial growth in both the agar plates and LJ slants.  
 
Conclusion: Different VCO preparations containing different amounts of lauric acid exhibited 
different  degree  of  inhibition  against  M.  tuberculosis.  The  result  of  the  study  suggests  the Functional Foods in Health and Disease 2012, 2(8):290-299                                                          Page 291 of 299 
 
potential of VCOs agent against the growth of  M. tuberculosis Similar effect on other organisms 
is a possibility and should also be explored. But more studies are needed to replicate the studies 
using different concentrations of VCOs, lauric acid and other fatty acids in VCO such as myristic 
acid, caproic or caprylic acids. 
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BACKGROUND: 
Despite the availability of efficacious treatment, tuberculosis (TB) remains one of the major 
public health problems in the world. The World Health Organization (WHO) estimated over 8.8 
million incident cases of TB in 2010 (140/100,000), of which 3.9 million (62/100,000) were 
smear-positives.  An  estimated  1.1  million  people  died  from  TB  in  2010  among  Human 
Immunodeficiency Virus (HIV)- negative cases of TB and additional 0.35 million deaths among 
HIV positive cases (1). The Philippines ranks ninth among the 22 high TB-burden countries in 
the world and  3
rd among the seven high-TB burden countries in the Western Pacific Region (1). 
Although tuberculosis is considered a curable disease, it ranks 6th among the top leading causes 
of mortality and morbidity in the Philippines (2). 
Based  on  reports  from  the  Department  of  Health  (DOH),  there  has  been  significant 
progress in the implementation of the Directly Observed Short- course Therapy for TB (DOTS) 
from 1996 to late of 2003 in the country. However, Dr. Woojin Lew, medical officer at WHO-
Philippines, said the Philippine government has “a long way to go” in terms of detecting, treating 
and curing highly infectious TB patients (2). He further expressed that highly infectious TB 
patients remains high in the Philippines (2, 3). Locally, 75 people are dying every day from the 
disease. (2,3). The National Tuberculosis Control of the Philippines (NTP) has demonstrated  
two components of DOTS which  are significantly related to improved clinical outcomes. These 
are government commitment to the program and continuous supply of anti-TB drugs to  patients. 
In a country where drug supply and reliable distribution continue to be a problem and poor 
sanitation and nutrition increase the probability of re-infection, adjunctive management for the 
control of TB can greatly improve its control. 
A clinical study by  Dayrit showed  that Virgin Coconut Oil (VCO)  beneficially reduced  
viral load among six AIDs patients confined in a Referral Hospital for Infectious Diseases in 
Manila. Although none of the study subjects survived at the end of the study, this was the first 
study on VCO for HIV patients in the country (4). Enig similarly reported that lauric acid, a 
medium-chain fatty acid that comprises 50% of the fatty acids in coconut fat is converted by the 
body into “monolaurin” (5, 6).This derivative is believed to be responsible for the anti-viral 
properties of VCOs.  As a precursor of monolaurin, lauric acid was shown to disrupt the lipid 
membranes of enveloped viruses. It is believed that monolaurin dissolves the lipids in the viral 
envelope  causing    their    disintegration.  It  can  also  inactivate  pathogenic  bacteria,  such  as, 
Listeria monocytogenes, Helicobacter pylori and recently Staphylococcus aureus, protozoa, like 
Giardia lamblia, yeast, such as, Candida albicans and other fungi (7, 8, 9). Other studies have 
shown  that  monolaurin  may  be  useful  in  the  prevention  and  treatment  of  severe  bacterial 
infections, especially those that are difficult to treat or are already resistant to antibiotics (8, 9).  Functional Foods in Health and Disease 2012, 2(8):290-299                                                          Page 292 of 299 
 
Since Mycobacterium tuberculosis has a lipid structure in its cell wall, it was theorized that the 
principal unsaturated fatty acid of VCO, lauric acid, is responsible for exerting the same  anti-
bacterial action  exhibited by  monolaurin on the walls of  pathogenic  bacteria. 
The country is one of the biggest exporters of coconut oil. VCO export earnings which 
surged by 138.65 percent to $7.56 million in January to March 2012 compared to the $3.17 
million recorded a year ago contribute significantly to the economy. Forbes reported that the 
volume of VCO exports also surged to 1,719.23 metric tons, 93.58 percent higher than the 888 
MT recorded a year ago (10). Thus, it is important that any health benefits attributed to VCO 
must be scientifically validated in order to maintain viability of the sale and promotion of VCO. 
In this study, we investigated the in vitro potential of VCO coming from the fruit of a highly 
abundant and indigenous tree, the coconut. The purpose of the study was not to challenge the 
current  efficacy  of  antibiotics  for  tuberculosis  but  to  explore      supplementary  or  adjunctive 
treatment for TB. The population expected to benefit most are patients residing in hard to reach 
communities  which  may  have  limited  or  inconsistent  access  to  anti-TB  drugs.  Thus,  it  was 
important for us to firstly document any antibacterial activity of VCO against M. tuberculosis.  
To achieve this objective, we worked on two preparations of VCO produced by two extraction 
methods and containing different amounts of lauric acid. Using in vitro susceptibility tests, we 
measured their inhibitory effects against M. tuberculosis isolates compared to a preparation of  
45% lauric acid  alone  and a   negative control containing the M. tuberculosis isolates. 
 
MATERIALS AND METHOD: 
All microbiologic tests for the study were performed at the Medical Research Laboratory of the 
Section  of  Infectious  Diseases  of  the  UP-Philippine  General  Hospital.  It  is  a  major  referral 
hospital in the Philippines. The technical working group was composed of a Pharmacologist, 
Pharmacist  and  Microbiologist  who  regularly  met  to  address  emerging  problems  during  the 
actual conduct of the test. These meetings occurred quite frequently since the test product was 
not the regular standardized  pharmaceutical preparation but rather a functional food. 
The VCO   samples were selected by the study trial monitor (Philippine Council for Health 
Research  and  Development,  PCHRD)  based on  existing sale data  of VCOs.  In addition,  we 
requested for VCO preparations produced by two extraction processes aside from having the 
highest sale in the market. The VCOs were submitted to the study site as coded specimens, 
namely VCO 013 and VCO 012.  
 
A. Test samples: VCO 013 was described by the manufacturer as 100% virgin and unrefined. Its 
product insert contains the following information about the preparation: “it is made from fresh-
picked coconuts and fresh-milled to attain a lauric acid content of 56%”. It   was not subjected to 
heat and did not undergo any processing such as bleaching and deodorizing. It was produced 
naturally from the kernels of carefully selected Philippine coconuts”. VCO 013 was prepared by 
the cold process-a no heat (ANH) process similar to the process of wet milling whereby oil is 
extracted from fresh coconut meat without drying first.  Wet milling means, "coconut milk" is 
expressed first by pressing. “The oil is then further separated from the water.  Methods which 
can  be  used  to  separate  the  oil  from  the  water  include  boiling,  fermentation,  refrigeration, 
enzymes and mechanical centrifuge” (11). In the case of VCO 013, centrifuging was used. Functional Foods in Health and Disease 2012, 2(8):290-299                                                          Page 293 of 299 
 
VCO 012 was  made from “genuinely pure Virgin Coconut Oil extracted from the choicest, 
freshest, and organically-grown Philippine coconuts; produced through Fresh-Dry method at the 
lowest temperature possible without chemical intervention. This is also known as “dry milling”. 
The coconut meat was quick dried, and the oil was then pressed out via mechanical means. This 
is the most common type of "Virgin" or "Extra Virgin" coconut oil sold in the market today. 
Except for the  fruity odor of VCO 012, the color, consistency  and general  appearances  of both 
preparations were indistinguishable. Claims have been made that the less heat used in producing 
VCO, the higher the content of antioxidants (12). The study group assumed that if there was a 
difference  in  antioxidants,  difference  in  inhibiting  the  growth  of  the  TB  isolates  might  be 
observed.  
Both VCOs were compared with 45%  lauric acid. This concentration was based on   the 
usual reported amount of lauric acid in local coconut oil ranging from 45-50%. They were also 
compared with a negative control containing 7H9 Broth plus the TB organism [ H37RV]. Anti- 
microbial property of all the test samples and comparators was tested against H37RV strain of M. 
tuberculosis obtained from the  Infectious Disease Section of UP Manila- Philippine General 
Hospital. 
 
B.  Procedure: 
1.  Preparation of the VCO test samples: The VCO test samples were prepared containing 
0.5 ml of the VCOs plus 5 ml of 7H9 broth. Initial tests were performed on the emulsified 
preparations. However, the emulsifying agent, CDEA, which was considered inert also  
inhibited growth of TB isolates in-vitro. Thus, the final test samples were the original 
forms sold commercially. 
2.  Preparation of H37RV  inoculum: A frozen stock of 1 x 10
8 CFU /mL M. tuberculosis 
H37RV was thawed and diluted with 7H9 with Albumin, Dextrose and Catalase (ADC) 
to  give a 1 x 10 
4 CFU/mL  concentration. ADC is an enrichment supplement to enhance 
the cultivation of Mycobacteria. 
3.  Preparation of the Middlebrook 7H10 Agar Plate: The Middlebrook 7H10 agar was 
prepared according to the manufacturer’s instruction.  The agar after sterilization was 
cooled in a water bath at 50⁰C to 56
0C.   Five milliliters of the agar was dispersed in 
duplicate plates and allowed to solidify.  The quadrant plates were placed in plastic bags 
and stored at 4⁰C to 8
0C. The prepared plates were used within 28 days after preparation. 
4.  In –vitro susceptibility test proper: Exactly 0.1mL of the prepared H37RV (1 x 10 
4 
CFU/mL) was added to each tubes containing the VCO samples, negative control and 
lauric acid. The mixtures were incubated at 37
0C for five days, with shaking for 5-10 
minutes every hour during daytime. After five days, each of the mixtures was diluted 10 
fold up to 10
-4. The quadrant plates with Middlebrook 7H10 agar was inoculated with 0.1 
mL of each dilution. The control plate was likewise inoculated with the corresponding 
diluted   H37RV. The same procedure was repeated using Lowenstein Jensen (L-J) slants. 
All quadrant plates and L-J slants were incubated at 37 
0C, and examined for growth 
every week for 3 to 8 weeks. 
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At the end of the incubation period, colonies on the quadrant plates and L-J slants were 
counted and recorded.  Colony counts in the test quadrants (test preparations + organism) were 
compared with the counts in the control quadrants (organism + broth).  As we performed more 
runs of the test, we noted the importance of ensuring longer contact time between VCO and the 
test  organism.  This  was  accomplished  by  continuous  shaking  and  vigorous  agitation  during 
incubation.  Additionally, the mixtures of H37RV and the test samples were allowed to react for 
5 days. Intermittent shaking for 10-15 minutes during daytime was done to further enhance the 
contact between organisms and test compounds.  At the end of the incubation period, the test 
preparations were diluted 10-fold to ensure that the colonies which will grow can be counted and 
do not overlap. 
 
RESULTS: 
Percentage amount of lauric acid in the test VCOs: The usual composition of coconut oil 
described by the literature is listed in Table 1 juxtaposed with the fatty acids present in the two 
VCOs in our study. Because of limited resources, the composition of the VCOs were obtained 
from tests done by the manufacturer and was not validated by the study group. Both VCOs 
contained amounts of lauric acid within the range acceptable for coconut oils. However, VCO 
013 contained 8.3% more of the lauric acid than the comparator VCO 012. Medical literature 
places the lauric acid content of most Virgin Coconut Oils  at around  45-53% (13). 
 
Table 1. Composition of fatty acids in the VCOs used in the study  
Common  Name  and  
Composition 
Percentage (%) 
Coconut oil  VCO 013  VCO 012 
Caproic      C 6:0  ND- 0.7  0.2  7.8 
Caprylic     C 8:0  4.6-10.0  5.0  6.7 
Capric        C 10:0  5.0-8.0  4.7  0.5 
Lauric        C 12:0  45.1-53.2  55.8  47.5 
Myristic      C 14:0  16.8-21.0  18.4   
Palmitic      C 16:0  7.5-10.2  8.0   
Palmitoleic  C 16:1  ND     
Stearic         C 18:0  2.0-4.0  2.2   
Oleic           C 18:1  5.0-10.0  5.5   
Linoleic      C 18:2  1.0-2.5  1.1   
Linolenic    C 18:3  ND-0.2     
Nervonic     C 24  ND     
 
ND= non detectable 
 
      Not surprisingly, we observed greater inhibition of the growth of TB isolates by VCO 013 which 
contained more lauric acid than VCO 012. Please see Table 2. The same ability of VCOs to 
inhibit  TB  growth  was  demonstrated  in  the  second  replicate.  We  observed  a  much  lower 
inhibitory  effect  of  VCO  013  for  the  same  concentrations  than  VCO  012.  This  might  be 
attributed  to  a  random  error  and  would  have  been  avoided  if  there  were  more  replicates. Functional Foods in Health and Disease 2012, 2(8):290-299                                                          Page 295 of 299 
 
Presently, we cannot provide an explanation for the results but it is possible that it is not the 
concentration of lauric acid per se that causes the antibacterial action of VCO but the ratio of a 
high lauric acid to the other fatty acids in coconut oils. Consistent though was the inhibitory 
effect of lauric acids in all replicates confirming the assumption that it might be the principle 
responsible for the antibacterial effect of coconut oils (8, 9, 14). 
 
Table 2. Colony count of TB in Middlebrook agar at increasing dilution of the control,  VCO 
samples  and lauric acid based  on two replicates 
 
 
In the following Figure, average colony counts of M. tuberculosis isolates were used. 
 
 
Figure 1. Average colony count of M.tuberculosis in Middlebrook agar at different dilution 
 
Of the two VCO brands, VCO 013 showed early and significant decrease in the number of TB 
colonies  starting  from  1:10  dilution  and  progressively  to  almost  complete  inhibition  of  M. 
tuberculosis growth at 1:10000 dilution. Another set of  susceptibility test was performed  using 
L-J slants. Growth of  M. tuberculosis in the L-J slant was more dispersed and easier to count.   
  Replicate 1  Replicate 2 
Dilution  Control 
VCO 
56% 
VCO 
47% 
Lauric 
acid 
(100%)  Control 
VCO    
56% 
VCO 
47% 
Lauric 
acid 
(100%) 
                 
Undiluted  560  560  560  0  560  560  560  0 
10⁻1  560  85  300  0  560  369  560  0 
10⁻2  312  0  169  0  312  120  111  0 
10⁻3  89  35  33  0  89  100  44  0 
10⁻4        103           1            0            0  103  16  15  0 Functional Foods in Health and Disease 2012, 2(8):290-299                                                          Page 296 of 299 
 
Table 3. Colony count of M. tuberculosis  in LJ slants at increasing  dilution of the control, VCO 
samples  and Lauric acid 
  Replicate 1 
Colony count of TB 
Replicate 2 
Colony count of TB  
Dilution  I  1
0
-1   
1
0
-2 
 
1
0
-3 
 
1
0
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4
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8  5
  
2 
Lauric acid  0 
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0  0  0  0 
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Figure 2. Average colony count of M. tuberculosis in LJ Slant in different dilutions 
 
Using Middlebrook 7H10 agar, both  VCO 012 and VCO 013  in 1:100 to 1:10000 dilution 
showed bacterial reduction or growth inhibition ranging from 46% to 100 % respectively. The 
same trend was noted for bacterial growth in L-J slants, with degree of inhibition ranging from 
25 % to 96%  shown in Table 3. The antibacterial effect of lauric acid was also confirmed in the 
L-J slant.  
 
Statistical analysis: Being preliminary in nature, data merely underwent descriptive analysis. 
Data was run in MS Excel version 2007 and charts generated by the same. Functional Foods in Health and Disease 2012, 2(8):290-299                                                          Page 297 of 299 
 
DISCUSSION: 
Coconut oil is composed of triglycerides made of medium-chain and saturated fatty acids which 
is primarily saturated and medium chain fatty acids. Its 92% saturated fat content raises concern 
over possible cardiovascular risk. However, coconut oil has a 62% concentration of Medium 
Chain Fatty acids (MCFAs) which is a unique characteristic that is not present in other saturated 
fat” (11, 12). Unsaturated fat have a high concentration of long chain fatty acids unlike MCFAs 
which are easily absorbed by the body as it require less energy and fewer enzymes. Short and 
medium  chain  fatty  acids  are  transported  directly  to  the  liver  where  they  are  immediately 
converted to energy (12). MCFA is suspected to prevent and heal a lot of sickness because of its 
antimicrobial properties. Aside from its ability to improve the immune system, MCFA also aids 
in the absorption and retention of magnesium, calcium and some amino acids (12). 
Colonies of the TB organisms were noted to be confluent and impossible to count in all the 
undiluted test samples in both media. Thus, a count of 560 is often used to place a quantitative 
value to confluent growth. Colonies of M. tuberculosis could only be counted beginning at a 
dilution of 1:100. At this dilution, both brands of commercial VCOs showed inhibition of M. 
tuberculosis growth by   as much as 46% to 100%. Growth of M. tuberculosis decreased from 
baseline by 72% in the sample with the VCO 013 containing 56% of Lauric acid and by 40% for 
the VCO 012 containing 47% of lauric acid.             
To confirm the viability of the test organisms, inocula taken from the mixtures of VCO and 
H37RV were inoculated into another medium, the Lowenstein Jensen (LJ) Medium. Grossly 
sufficient growth of the mycobacteria was shown in the LJ slant containing none of the VCOs 
and control materials.  Results from the LJ slants also showed the inhibitory effects of both VCO 
012 and VCO 013 on H37RV. However, literatures dealing on the L-J medium reported some 
limitations using the media on recovering isolates of M. tuberculosis (14). For example, a study 
conducted  in  India  in  2005  compared  the  biphasic  system  (Middlebrook  7H11  agar  slant  + 
Middlebrook 9H broth) with Lowenstein - Jensen (LJ) medium. In smear positive cases, the 
biphasic system showed a recovery rate of 97.05% as against 79.41% on L-J on incubation for 
21±  4.44  and  28±3.76  days  respectively.  In  smear  negative  and  culture  positive  cases,  the 
biphasic system and -LJ showed isolation rates of 91.66% and 66.6% after 36±3.44 and 41± 4.09 
days  respectively.  This  suggests  that  the  biphasic  system  showed  lower  contamination  rate 
(1.33%). It also concluded that the Biphasic medium is superior to L-J medium in isolating M. 
tuberculosis (15). But there was no difference between LJ slant and Middlebrook agar observed 
in our study. 
Differences in inhibitory potential between the two commercial brands of VCO may be 
attributed to differences in the manner that they have been produced. This can be explained by 
studies showing different amount of oils based on different extraction methods. However, this 
was refuted by the study of Professor Dia (2005) of the University of the Philippines who studied 
three batches of VCO produced by three extraction methods. The values that were tested in all 
these VCOs were: melting point, gravity, saponification, iodine, free fatty acid (FFA), peroxide 
value, moisture content, fatty acid composition, tocopherols, and total phenolic content. Their 
results found that: "while the VCOs produced by the three methods and using different varieties 
had some differences in chemical and quality properties, these differences may not be large 
enough to significantly affect the overall quality of the VCO” (16). There is no industry standard Functional Foods in Health and Disease 2012, 2(8):290-299                                                          Page 298 of 299 
 
definition for "Virgin Coconut Oil" as there is in the olive oil industry for "Virgin" and "Extra 
Virgin" olive oil.  
 
CONCLUSION AND LIMITATIONS: The study using in-vitro method to test virgin coconut 
oil, an oil- based substance, against M. tuberculosisr showed the potential of   VCOs against 
infection from the mycobacterial species (H37RV). The same action was likewise noted with 
45% lauric acid. However, the study is limited by the insufficient number of replicates. The 
actual lauric acid content for both brands of the VCO was not validated by actual assay. Results 
of the agar and L-J slant showed consistent trend for inhibiting growth of TB isolates by both  
VCOs independent of  the brand. Greater inhibition was observed with VCO 013 containing 56% 
lauric acid than VCO 012 with 47% lauric acid during the initial run. This observation was 
reversed on the second run in favor of the latter.  VCO with more lauric acid content showed 
earlier onset of action. Further studies are needed to determine the effective and lethal dose of  
VCO  among humans. The possible anti-tuberculosis action of VCO in-vitro opens the door for 
clinical  trials  of  other  indigenous  plant  product  against  tuberculosis  or  as  an  adjunct  to  TB 
therapy. Prior to the discovery of streptomy cin, tuberculosis was partially eradicated by non 
pharmaceutical interventions such as improvement in sanitation and nutrition. It is not far fetched 
to expect VCO, which is rich in protein, to enhance the body’s response to antibiotics.  However, 
more studies are needed using varying and precise doses of lauric acid and VCOs in patients with 
tuberculosis.  Randomized  clinical  trials  adding  VCO  to  the  usual  anti-TB  drugs  should  be 
conducted  and  clinical  responses  of  patients,  such  as  early  microbial  cure,  improvement  of 
nutritional state and treatment success must be documented.  
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